Human Immunology Biosciences, a biotechnology company, agreed to acquire a minority stake in MorphoSys, a biotechnology company. Financial terms were not disclosed. “At HIBio, we are discovering and developing transformative precision therapies for patients with autoimmune and inflammatory diseases. We are excited that we’ve reached this deal with MorphoSys, which will allow us to realize the potential of felzartamab and MOR210 across multiple autoimmune diseases,” Travis Murdoch, HIBio CEO.